Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose, including respiratory depression. The increasing cases of opioid addiction and overdose deaths have fueled the demand for naloxone. Easy availability and administration of naloxone helps reduce harm and prevents fatalities in case of an overdose emergency.

The global Naloxone Market is estimated to be valued at US$ 1234.6 Mn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing rate of opioid overdose deaths due to addiction has been a major factor driving the growth of the naloxone market. According to the National Institute on Drug Abuse, opioid overdose deaths saw a significant increase over the past few decades. It rose from 8,000 deaths in 1999 to over 47,000 in 2019 in the U.S. alone. Various initiatives undertaken by public and private organizations to make naloxone available over-the-counter without a prescription have increased accessibility. This is expected to further escalate the demand and aid in reducing preventable deaths in emergency opioid overdose situations.

SWOT Analysis

Strength: Naloxone has a long history of safe and effective administration to reduce opioid overdose mortality. It works as an opioid antagonist that can rapidly reverse overdose effects from other opioids.

Weakness: Naloxone requires administration by another person during an overdose, limiting its impact for solitary drug use. Repeat dosing is sometimes needed if the underlying opioids have a very long duration of action like fentanyl.

Opportunity: Expanded public distribution programs and co-prescribing with opioids can improve access and overdose response during emergency situations. Rising rates of opioid use disorder and overdoses represent a growing treatment need.

Threats: Competition from generic drug manufacturers may cut into profits for branded naloxone products. Social stigma remains for those suffering from substance use disorders, creating barriers to treatment.

Key Takeaways

The Global Naloxone Market Demand is expected to witness high growth driven by the rising opioid overdose epidemic. The global Naloxone Market is estimated to be valued at US$ 1234.6 Mn in 2023 and is expected to exhibit a CAGR of 4.7% over the forecast period 2023 to 2030.

North America currently dominates the market due to higher usage of opioids and policy support for naloxone access in countries like the US. The region's naloxone market is expected to grow at a CAGR of 4.5% during the forecast period. Europe is also a major naloxone market supported by initiatives to expand access across countries dealing with growing opioid problems. However, social and economic barriers still limit treatment rates for opioid use disorder. The European naloxone market is projected to increase at a 4.6% CAGR through 2030.

Key players operating in the naloxone market are Beiersdorf AG, Procter & Gamble, Unilever, Bioderma Laboratories, Clarins Group, Dermalume Skincare, Johnson & Johnson Inc., Estee Lauder Inc., Miranda Kerr Pty Ltd (Kora Organics), Jurlique International Pty Ltd, and Natio. These companies compete based on portfolio expansion, innovative drug delivery formats, and marketing campaigns to expand patient and community access to naloxone.

For more insights, Read- https://www.pressreleasebulletin.com/naloxone-market-trends-size-and-share-analysis/

Get more insights on this topic: https://www.shayaricenter.com/understanding-cancer-biomarkers